Sensorion SA Asset Resilience Ratio
Sensorion SA asset resilience ratio. Sensorion SA (ALSEN) has an Asset Resilience Ratio of 92.55% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sensorion SA (ALSEN) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sensorion SA (2016–2025)
Asset resilience ratio of Sensorion SA from 2016 to 2025. This chart shows how Sensorion SA's Asset Resilience Ratio has changed over time. Read Sensorion SA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sensorion SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALSEN total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €26.79 Million | 46.27% |
| Short-term Investments | €26.79 Million | 46.27% |
| Total Liquid Assets | €53.57 Million | 92.55% |
Asset Resilience Insights
- Very High Liquidity: Sensorion SA maintains exceptional liquid asset reserves at 92.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company maintains a balanced mix of cash and short-term investments.
Sensorion SA Industry Peers by Asset Resilience Ratio
Compare Sensorion SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Sensorion SA Asset Resilience Ratio by Year (2016–2025)
Sensorion SA asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Sensorion SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 92.55% | €53.57 Million ≈ $62.63 Million |
€57.89 Million ≈ $67.68 Million |
+22.91pp |
| 2024-12-31 | 69.64% | €62.18 Million ≈ $72.69 Million |
€89.28 Million ≈ $104.37 Million |
+34.24pp |
| 2020-12-31 | 35.41% | €24.03 Million ≈ $28.09 Million |
€67.87 Million ≈ $79.35 Million |
+9.15pp |
| 2019-12-31 | 26.25% | €10.00 Million ≈ $11.69 Million |
€38.09 Million ≈ $44.53 Million |
+26.08pp |
| 2018-12-31 | 0.17% | €16.00K ≈ $18.71K |
€9.47 Million ≈ $11.07 Million |
-85.87pp |
| 2017-12-31 | 86.04% | €9.60 Million ≈ $11.23 Million |
€11.16 Million ≈ $13.05 Million |
+14.10pp |
| 2016-12-31 | 71.94% | €8.53 Million ≈ $9.97 Million |
€11.85 Million ≈ $13.86 Million |
-- |
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutat… Read more